Sangamo (SGMO) Reports Positive Preliminary Data from Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A
Go back to Sangamo (SGMO) Reports Positive Preliminary Data from Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A| Sangamo Biosciences, Inc. (NASDAQ: SGMO) | Delayed: 0.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.49 | 52 Week High | $9.91 | |||
| Open | $0.49 | 52 Week Low | $3.10 | |||
| Day High | $0.49 | P/E | N/A | |||
| Day Low | $0.49 | EPS | $-0.48 | |||
| Volume | 7,101 | |||||
